- United States
- /
- Biotech
- /
- NasdaqCM:DYAI
Dyadic International Second Quarter 2024 Earnings: Misses Expectations
Dyadic International (NASDAQ:DYAI) Second Quarter 2024 Results
Key Financial Results
- Revenue: US$385.9k (down 54% from 2Q 2023).
- Net loss: US$2.05m (loss narrowed by 5.0% from 2Q 2023).
- US$0.07 loss per share (improved from US$0.075 loss in 2Q 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Dyadic International Revenues and Earnings Miss Expectations
Revenue missed analyst estimates by 61%. Earnings per share (EPS) also missed analyst estimates by 7.7%.
Looking ahead, revenue is forecast to grow 45% p.a. on average during the next 3 years, compared to a 23% growth forecast for the Biotechs industry in the US.
Performance of the American Biotechs industry.
The company's share price is broadly unchanged from a week ago.
Risk Analysis
Before you take the next step you should know about the 6 warning signs for Dyadic International (1 is potentially serious!) that we have uncovered.
If you're looking to trade Dyadic International, open an account with the lowest-cost platform trusted by professionals, Interactive Brokers.
With clients in over 200 countries and territories, and access to 160 markets, IBKR lets you trade stocks, options, futures, forex, bonds and funds from a single integrated account.
Enjoy no hidden fees, no account minimums, and FX conversion rates as low as 0.03%, far better than what most brokers offer.
Sponsored ContentNew: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About NasdaqCM:DYAI
Dyadic International
A biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally.
Excellent balance sheet slight.